HHS renews fight to require drug prices in TV ads

HHS has appealed a July court ruling that blocked a regulation that would have required drugmakers to include list prices in direct-to-consumer TV advertisements, according to STAT. 

U.S. District Judge Amit Mehta ruled July 8 that the Trump administration didn't have the authority to issue the rule, which prevented the rule from taking effect July 9 as planned. 

The rule was announced in May as part of President Donald Trump's blueprint to lower prescription drug costs in the U.S. Under the blocked rule, drugmakers would have to include the list price of their drugs if a month's supply cost $35 or more.

Merck, Eli Lilly and Amgen, filed the initial lawsuit to block the rule in June, arguing that it would confuse customers and it violated drugmakers' freedom of speech. 

The Trump administration contends that drugmakers don't want to comply with the rule because they are ashamed of their prices.

Read the full report here

More articles on pharmacy:
FDA approves AbbVie's $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers